NO20041815L - Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon - Google Patents

Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon

Info

Publication number
NO20041815L
NO20041815L NO20041815A NO20041815A NO20041815L NO 20041815 L NO20041815 L NO 20041815L NO 20041815 A NO20041815 A NO 20041815A NO 20041815 A NO20041815 A NO 20041815A NO 20041815 L NO20041815 L NO 20041815L
Authority
NO
Norway
Prior art keywords
hepatitis
methods
virus infection
liver fibrosis
treating liver
Prior art date
Application number
NO20041815A
Other languages
English (en)
Inventor
Henry H Hsu
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of NO20041815L publication Critical patent/NO20041815L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Power Sources (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20041815A 2001-10-05 2004-05-04 Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon NO20041815L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32774301P 2001-10-05 2001-10-05
PCT/US2002/030838 WO2003030613A2 (en) 2001-10-05 2002-10-03 Methods of treating liver fibrosis and hepatitis c virus infection

Publications (1)

Publication Number Publication Date
NO20041815L true NO20041815L (no) 2004-06-11

Family

ID=23277847

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041815A NO20041815L (no) 2001-10-05 2004-05-04 Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon

Country Status (15)

Country Link
US (1) US20050013801A1 (no)
EP (1) EP1450848A4 (no)
JP (1) JP2005508935A (no)
KR (1) KR20050033518A (no)
CN (1) CN1564693A (no)
AR (1) AR036727A1 (no)
BR (1) BR0213093A (no)
CA (1) CA2460341A1 (no)
HU (1) HUP0600449A2 (no)
IL (1) IL161022A0 (no)
MX (1) MXPA04003239A (no)
NO (1) NO20041815L (no)
PL (1) PL371683A1 (no)
WO (1) WO2003030613A2 (no)
ZA (1) ZA200402353B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
JPWO2006033453A1 (ja) * 2004-09-22 2008-05-15 学校法人順天堂 インターフェロン作用物質の活性増強剤
KR20090037347A (ko) * 2007-10-10 2009-04-15 한올제약주식회사 ＨＭＧ－ＣｏＡ 환원효소억제제와 담즙산을 포함하는 Ｃ형 간염 치료용 약학조성물
KR20220042485A (ko) * 2012-01-16 2022-04-05 엘라자베스 맥켄나 간 질환들 및 장애들의 치료를 위한 조성물들 및 방법들

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096705A (en) * 1981-10-19 1992-03-17 Genentech, Inc. Human immune interferon
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US4462986A (en) * 1982-11-04 1984-07-31 Ens Bio Logicals, Inc. Synergistic anti-herpes compositions
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
IL76591A0 (en) * 1984-10-05 1986-02-28 Bioferon Biochem Substanz Pharmaceutical compositions containing ifn-ypsilon and processes for the preparation thereof
US4806347A (en) * 1985-12-11 1989-02-21 Schering Corporation Interferon combinations
US5082659A (en) * 1986-10-06 1992-01-21 Board Of Regents, The University Of Texas System Methods and compositions employing interferon-gamma
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
US5190751A (en) * 1987-01-20 1993-03-02 Schering Corporation Treatment of certain leukemias with a combination of gamma interferon and alpha interferon
WO1988009673A1 (en) * 1987-06-02 1988-12-15 Schering Corporation Treatment of chronic type b hepatitis with a combination of recombinant human alpha and gamma interferons
US5215744A (en) * 1987-06-16 1993-06-01 Boehringer Ingelheim Gmbh Methods for the treatment of tumors
DE69032841T2 (de) * 1989-01-23 1999-05-12 Chiron Corp., Emeryville, Calif. Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
US5141735A (en) * 1990-06-18 1992-08-25 Hoffman-La Roche, Inc. Substituted amino-benzodiazepines having anitviral activity
TW224053B (no) * 1991-09-13 1994-05-21 Paul B Chretien
EP0625991B1 (en) * 1992-02-10 1999-04-28 Interferon Sciences, Inc. Improved alpha interferon composition and method for its production from human peripheral blood leukocytes
US6077519A (en) * 1993-01-29 2000-06-20 University Of Pittsburgh Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
US6200952B1 (en) * 1993-06-02 2001-03-13 Sciclone Pharmaceuticals, Inc. Combination therapy method for treating chronic hepatitis B
US5830448A (en) * 1994-06-16 1998-11-03 Genentech, Inc. Compositions and methods for the treatment of tumors
US5565558A (en) * 1994-12-30 1996-10-15 Mccully; Kilmer S. Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon
US5980884A (en) * 1996-02-05 1999-11-09 Amgen, Inc. Methods for retreatment of patients afflicted with Hepatitis C using consensus interferon
EP1023901A4 (en) * 1997-10-13 2004-10-27 Otsuka Pharma Co Ltd MEDICINES FOR HEPATITIS C AND THE USE THEREOF
KR20020020809A (ko) * 1999-08-13 2002-03-15 프리돌린 클라우스너, 롤란드 비. 보레르 페길화-인터페론-알파와 관련된 미코페놀레이트 모페틸

Also Published As

Publication number Publication date
WO2003030613A3 (en) 2003-11-06
JP2005508935A (ja) 2005-04-07
AR036727A1 (es) 2004-09-29
EP1450848A2 (en) 2004-09-01
PL371683A1 (en) 2005-06-27
US20050013801A1 (en) 2005-01-20
IL161022A0 (en) 2004-08-31
HUP0600449A2 (en) 2006-09-28
ZA200402353B (en) 2006-03-29
BR0213093A (pt) 2005-03-15
EP1450848A4 (en) 2005-11-09
CA2460341A1 (en) 2003-04-17
KR20050033518A (ko) 2005-04-12
WO2003030613A2 (en) 2003-04-17
MXPA04003239A (es) 2004-07-08
CN1564693A (zh) 2005-01-12

Similar Documents

Publication Publication Date Title
NO20025627L (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
IS7530A (is) Lifrarbólgu C-veirutálmar
DE60139127D1 (de) Von hepatitis c virus
NO20020400L (no) Sekvenser og metoder for deteksjon av hepatitt C virus
NO20004104D0 (no) Preparater omfattende virus og fremgangsmÕter for konsentrering av viruspreparater
AU2002230763A8 (en) Inhibitors of hepatitis c virus ns3 protease
NO20041814L (no) Fremgangsmate for a behandle hepatitt virusinfeksjoner med en mulitfaseinterferonavleveringsprofil
DK1210112T3 (da) Vaccine mod HBV og HPV
CY2016018I2 (el) Εμβολιο κατα του ιου του δυτικου νειλου
IS7830A (is) Bóluefni gegn lifrarbólgu C veiru (HCV)
NO20030239D0 (no) Modifisert virus
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
IL157251A0 (en) Hepatitis b virus treatment
IL162236A0 (en) Purified hepatitis c virus envelopeproteins for dagnostic and therapeutic use
NO20033829L (no) Virusdrepende preparater
AU2003294757A8 (en) Formulations useful against hepatitis c virus infections
IS5777A (is) Bóluefnisvakið lifrarbólgu B veiruafbrigði og notkun þess
IL143798A0 (en) Hepatitis c virus ns3 protease
NO20041815L (no) Fremgangsmater for a behandle leverfibrose og hepatitt C-virusinfeksjon
AU2001269092A1 (en) Inhibitors of hepatitis b virus infection
AU2003230790A8 (en) Hepatitis c virus sub-genomic replicons
AU2001234596A1 (en) Use of castanospermine and substituted-castanospermine compounds for treating hepatitis virus infections
NO20020399L (no) Sekvenser og fremgangsmåter for deteksjon av hepatitt B-virus
AU2003287216A8 (en) Gb virus c and methods of treating viral infections
IS2797B (is) Bóluefni gegn ISA-veiru